LLY vs ABBV
Eli Lilly and Company vs AbbVie Inc. · Updated May 11, 2026
LLY — 14 winsABBV — 7 wins
Price Performance
LLY +27.98%ABBV +6.69%
Performance
| LLY | ABBV | |
|---|---|---|
| 1 Month | +3.23% | -2.64% |
| 3 Months | -7.43% | -9.24% |
| 6 Months | +3.16% | -7.49% |
| YTD | -10.02% | -11.31% |
| 1 Year | +28.69% | +9.19% |
| 3 Year | +167.88% | +37.51% |
| 5 Year | +540.79% | +77.91% |
Yearly Returns
| YTD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | -10.5% | +37.4% | +30.4% | +59.7% | +35.1% | +66.9% | +27.7% | +14.4% | +36.7% | +13.2% | -11.3% | +20.3% |
| ABBV | -11.6% | +27.3% | +11.2% | -4.6% | +19.3% | +28.4% | +19.6% | -0.8% | -6.3% | +55.0% | +8.7% | -10.1% |
Valuation
| LLY | ABBV | |
|---|---|---|
| P/E Ratio | 34.35 | 99.37 |
| Forward P/E | 24.06 | 14.13 |
| PEG Ratio | 1.77 | 6.97 |
| P/S Ratio | 12.91 | 5.77 |
| P/B Ratio | 29.89 | -107.64 |
| EV/EBITDA | 29.44 | 12.66 |
Financials
| LLY | ABBV | |
|---|---|---|
| EPS (TTM) | $28.15 | $2.04 |
| Gross Margin | +78.98% | +83.54% |
| Operating Margin | +46.44% | +31.56% |
| Net Margin | +37.36% | +4.66% |
| ROE | +81.01% | -130.92% |
| ROA | +21.68% | +3.15% |
| Debt/Equity | 1.39 | -21.34 |
Growth
| LLY | ABBV | |
|---|---|---|
| Revenue Growth YoY | +55.55% | +12.43% |
| Revenue Growth QoQ | +2.63% | -9.72% |
| EPS Growth YoY | +169.94% | -45.83% |
| EPS Growth QoQ | +11.77% | -61.76% |
Technical
| LLY | ABBV | |
|---|---|---|
| RSI (14) | 59.09 | 44.48 |
| % From 20-Day SMA | +4.38% | -0.86% |
| % From 50-Day SMA | +2.89% | -4.28% |
| % From 200-Day SMA | +5.45% | -7.21% |
| % From 52-Week High | -14.72% | -17.23% |
| % From 52-Week Low | +55.03% | +14.76% |
Analyst Ratings
LLY
Buy(27 analysts)
Strong SellHoldStrong Buy
Price Target
$1261.11
+32.72% upside
ABBV
Buy(18 analysts)
Strong SellHoldStrong Buy
Price Target
$256.69
+27.72% upside
Overview
| LLY | ABBV | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Exchange | NYSE | NYSE |
| Market Cap | $932.64B | $362.56B |
| Shares Outstanding | 941.7M | 1.77B |
| Avg Volume (10D) | 4.02M | 6.59M |
| Dividend Yield | 0.70% | 3.29% |
Frequently Asked Questions
Is LLY or ABBV a better buy right now?
Based on 21 comparable metrics, LLY leads in 14 categories while ABBV leads in 7. LLY has a consensus analyst rating with 27 analysts covering the stock. Neither stock should be purchased based on a single comparison — consider your investment goals and risk tolerance.
Which stock has better performance, LLY or ABBV?
Over the past year, LLY returned +28.69% compared to ABBV's +9.19%. In the short term (1 month), LLY returned +3.23% vs ABBV's -2.64%.
Is LLY or ABBV more expensive?
LLY trades at a P/E of 34.35 compared to ABBV's 99.37. On a price-to-sales basis, LLY trades at 12.91x vs ABBV's 5.77x. Forward P/E: LLY at 24.06 vs ABBV at 14.13.
Which stock has higher growth, LLY or ABBV?
LLY's revenue grew +55.55% year-over-year compared to ABBV's +12.43%. EPS growth: LLY at +169.94% vs ABBV at -45.83%.
Do LLY and ABBV pay dividends?
LLY pays a dividend with a yield of 0.70%. ABBV pays a dividend with a yield of 3.29%.
Which stock do analysts prefer, LLY or ABBV?
LLY has 27 analysts with a target price of $1261.11 (+32.72% upside). ABBV has 18 analysts with a target of $256.69 (+27.72% upside).
Data updated daily. All comparisons based on latest available market data. Not investment advice.